news & meetings - latest announcements & happenings | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
https://media-www.fapvoice.com/wp-content/uploads/2017/07/canprev.gif
clinical trials

Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer

Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer. The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
Jul 17, 2017
https://media-www.fapvoice.com/wp-content/uploads/2017/08/Colon-cancer-1.jpg
research

Colon cancer discovery may aid prevention, treatment

Virginia Commonwealth University (VCU) researchers have discovered a new way in which colon cancer develops, as well as a potential silver bullet for preventing and treating the disease. Findings by VCU Massey Cancer Center scientists may extend to ovarian, breast, lung, prostate and potentially other cancers that depend on the same mechanism for growth. Researchers said the work involved targeting the gene CtBP with a drug known as HIPP, which allowed them to reduce the development of pre-cancerous polyps by half and return a normal lifespan to mice born with a predisposition to intestinal polyps.
Jul 31, 2017